Laurus Labs Ltd.'s fourth-quarter profit rose to Rs 234 crore, beating analysts' estimates.
The net profit of the Hyderabad-based pharma and biotech company increased 200% year-on-year in the quarter ended Mar 2025, according to an exchange filing on Thursday. That compares with the Rs 189 crore consensus estimate of analysts tracked by Bloomberg.
Laurus Labs Q4 FY25 Highlights (Consolidated, YoY)
Revenue up 19.5% to Rs 1,720 crore versus Rs 1,440 crore (Bloomberg estimate: Rs 1,645 crore).
Ebitda up 74% to Rs 421 crore versus Rs 242 crore (Estimate: Rs 414 crore).
Ebitda margin expanded to 24.4% versus 16.8% (Estimate: 25.2%).
Net profit up at Rs 234 crore versus Rs 76 crore (Estimate: Rs 189 crore)
Other income at Rs 58.6 crore versus Rs 18.5 crore
Shares of Laurus Labs were trading 0.84% lower at Rs 645.25 apiece as compared to 0.34% fall in the benchmark Nifty.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
